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Bone Morphogenetic Proteins (BMPs), together with Transforming Growth Factor (TGF)-b and Activ-
ins/Inhibins constitute the TGF-b superfamily of ligands. This superfamily is formed by more than 30
structurally related secreted proteins. Since TGF-b members act as morphogens, either a strict rela-
tion between a particular ligand to a distinct cellular receptor and/or temporospatial expression pat-
terns of ligands and receptors is expected. Instead, only a limited number of receptors exist
implicating promiscuous interactions of ligands and receptors. Furthermore, in complex tissues a
multitude of different ligands can be found, which signal via overlapping subsets of receptors. This
raises the intriguing question how concerted interactions of different ligands and receptors gener-
ate highly speciﬁc cellular signals, which are required during development and tissue homeostasis.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Complexity of an organism correlates with cytokine
superfamily size
For their development, maintenance and survival multicellular
organisms require constant intercellular communication to regu-
late all aspects of cellular life such as differentiation, proliferation,
migration or apoptosis. No matter whether these are paracrine,
endocrine or eventually autocrine stimuli the regulatory mecha-
nisms although not exclusively but very frequently involve
protein–protein interactions between a cell surface-located trans-
membrane receptor and a protein hormone also termed ligand.
As nature seems to recycle ‘‘successful’’ protein scaffolds/struc-
tures and to develop new functionalities by duplicating genes
rather than inventing de novo structures for each function, ligands
and their receptors often form superfamilies with the number of
members rising with increasing complexity of the organism [1]
(the degree of complexity can be correlated with the number of
different specialized cell types [2,3]). The Transforming Growth
Factor (TGF)-b superfamily is no exception to this observation,
with ﬁve potential ligand members in worm (Caenorhabditis ele-
gans) [4], seven ligands in ﬂy (Drosophila melanogaster) [5], 12 in
ﬁsh (Danio rerio), 16 in amphibia (Xenopus laevis) and more than
30 ligand members in mammals (see online resources in [6]). Con-
sistent with the hypothesis above, it seems that ligands having
essential functions during early development have orthologs inal Societies. Published by Elsevier
rg.de (T.D. Mueller).all of the aforementioned phyla. For instance, orthologs of
BMP-4, which is essential during early embryonic development
of vertebrates [7], can be found in ﬂy (Decapentaplegic, Dpp), in
zebraﬁsh (zBMP-4) as well as in amphibia (xBMP-4) sharing simi-
lar functions and mechanisms for dorsoventral patterning [8]. Only
C. elegans does not seem to have a direct ortholog of the mamma-
lian BMP-4, the genes encoding for the four ligand members, of
which daf7, dbl1, and tig2 are mapped to the human TGF-b ligands
GDF-11, BMP-5 and BMP-8. The two factors Daf-7 and Dbl-1 are in-
volved in the so-called Dauer larval development pathway regulat-
ing the body size of the larvae based on environmental conditions
[4]. The function of orphan worm TGF-b member Tig-2 is unclear
and Unc-129 mutant animals have been described to exhibit de-
fects in axon outgrowth [9,10]. Thus the ligands present in worm
seem to have functionalities other than patterning as is observed
in other invertebrates and vertebrates [10]. Other TGF-b members
have likely evolved later and exhibit functions restricted to higher
organisms; e.g. GDF-9/BMP-15, which are involved in ovarian
follicle development [11], the Anti-Muellerian Hormone (AMH),
which plays an important role in male sex differentiation [12].
2. The TGF-b superfamily comprises four subfamilies
On the basis of their biological functions and phylogenetic anal-
yses the more than 30 TGF-b ligands in mammals can be arranged
in four main subfamilies (Fig. 1A). The Activin/Inhibin subfamily
has initially been identiﬁed to regulate the expression of the pitu-
itary Follicle-Stimulating Hormone (FSH) in the gonads ([13] forB.V. Open access under CC BY-NC-ND license.
Fig. 1. (A) Phylogenetic analysis of the TGF-b ligand superfamily (only the mature region was used) showing the existence of four subfamilies as indicated on the left: BMP/
GDF (1), Activin/Inhibin/Nodal (2), TGF-bs (3) and others (4). Type I and type II receptor usage is indicated next to each ligand and deduced from biophysical interaction or
in vitro pulldown and crosslinking analyses. Light-blue shaded boxes emphasize SMAD 1/5/8, whereas light-red shaded boxes highlight SMAD 2/3 downstream signaling. (B)
Phylogenetic tree (kinase domains were used for analysis) of TGF-b receptors highlighting type I and type II subgroup classiﬁcation. Color usage for type I receptors indicates
the SMAD pathway utilized (as in A). (C) TGF-b ligands are synthesized as dimeric proproteins including an N-terminal signal peptide (SP), a large prodomain and a C-terminal
mature part with a characteristic cystine-knot motif. Cysteine residues are illustrated by red bars. Proteolytic processing by furin proteases occurs at the RXXR motif.
Indicated by the single asterisk are the two intermolecular disulﬁde bonds, which are exclusive to TGF-b1/2/3 and covalently link the prodomain dimer. The intermolecular
disulﬁde bond in the dimer of the mature part is marked by two asterisks (Lefty-1, -2, GDF-3, GDF-9 and BMP-15 lack this disulﬁde bond). (D) The architecture of TGF-b type I
and type II receptor architecture consists of an N-terminal extracellular ligand-binding domain (EC), a single span-transmembrane and an intracellular kinase domain. The
extracellular parts comprise ten cysteines in both receptor subtypes, but with a distinct sequential arrangement. An intracellular glycine/serine-rich domain (GS-box)
characteristic for type I receptors is essential for kinase and downstream SMAD pathway activation.
T.D. Mueller, J. Nickel / FEBS Letters 586 (2012) 1846–1859 1847recent review see [14]). However outside the gonads, Activins have
additional functions, e.g. mesoderm induction, which is important
for early body pattern determination and organogenesis (for re-
view [15]) or in inﬂammation and immunity (for review [16])
(Fig. 1A). The subfamily members Nodal together with the more
distant factors Lefty-1/-2 (that act as inhibitor to Nodal) are re-
quired for establishing left-right asymmetry [17] and Nodal itself
is possibly also involved in maintaining embryonic stem (ES) cells
in an undifferentiated state [18]. The subfamily of the TGF-b factors
is the likewise smallest with only three members in mammals:
TGF-b1, TGF-b2 and TGF-b3 (Fig. 1A). The TGF-bs are pleiotropic
factors controlling proliferation and differentiation of many differ-ent cell types, thus TGF-b functions have been implicated in the
control of immunity (e.g. by inducing FoxP3-positive regulatory
T-cells a.k.a. iTregs) [19], in wound healing (e.g. promoting ﬁbrosis
through induction of extracellular matrix synthesis in different tis-
sues and organs) [20] or for embryonic development [21]. How-
ever, best known is their dual role in the development and
progression of cancer. Normally, TGF-b inhibits growth of most cell
types including epithelial, endothelial and hematopoietic cells by
blocking the cell cycle in the G1 phase thereby acting as tumor
suppressor. But as a potent inducer of the epithelial-to-mesenchy-
mal transition required for TGF-b’s function in wound sealing, it
enables carcinoma cells to spread and metastasize into normal
1848 T.D. Mueller, J. Nickel / FEBS Letters 586 (2012) 1846–1859tissue at later stages of cancer progression [22]. Despite high se-
quence identities between the three TGF-b isoforms isoform-spe-
ciﬁc functions have been described [23].
The largest TGF-b subfamily is the group of Bone Morphoge-
netic Proteins (BMPs) and Growth and Differentiation Factors
(GDFs), which comprises more than 15 ligands in human
(Fig. 1A). Based on sequence similarities and their diversity in func-
tions this subfamily can be further subdivided into the BMP-2/-4,
the BMP-5/-6/-7/-8, the GDF-5/-6/-7, the GDF-8/-11, the BMP-
9(GDF-2)/BMP-10, the GDF-1/-3 and the GDF-10/BMP-3 sub-
groups. Although the name suggests that all BMP members of the
subfamily can induce bone growth – BMP-2 and BMP-7 have in-
deed been identiﬁed through their osteoinductive properties –
comparative analysis showed that the osteoinductive capabilities
of individual factors vary in potency as well as to which cell type
is susceptible [24]. From gene inactivation studies in mice it be-
comes obvious that BMP and GDF members have various other
functions (for review [25]). Bmp2 knockout mice die due to am-
nion/chorion defects showing that BMP-2 is an important factor
for heart development [26]. Bmp4 deﬁcient mice show mesoderm
defects in early gastrulation [7], but BMP-4 is also involved in
development of various organs, in limb patterning and skeletogen-
esis [27,28]. Deletion of Bmp7 shows that it is critical for kidney
development, but it also plays an important role in skeletogenesis,
eye and heart development and neurogenesis [29–31]. Other mem-
bers, e.g. BMP-3, BMP-5, BMP-6, BMP-8, GDF-5/-6/-7, GDF-8, GDF-
10, GDF-11 could be genetically removed without causing lethality
pointing towards functional redundancy in skeletal, heart and limb
development [32–37]. Some BMP/GDF ligands exhibit rather spe-
ciﬁc biological functions. For instance, deletion of Gdf8 leads to a
massive increase in skeletal muscle mass [38]. Mutations occurring
in cattle [39] and in human [40,41] conﬁrm that GDF-8 is a nega-
tive regulator of muscle growth. Changes in expression level in
cardiomyocytes after infarct suggest that GDF-8 is not only in-
volved in muscle growth during development but also exhibits a
regenerative function throughout life [42]. Interestingly, GDF-11,
which shares extremely high amino acid sequence similarity with
GDF-8 (98% similarity and 90% identity between mature human
GDF-8 and GDF-11), reveals a completely distinct function in vivo.
Deletion of Gdf11 in mice resulted in an increased number of ver-
tebral segments [43] and muscle-speciﬁc conditional deletion of
Gdf11 in mice shows that GDF-11 despite being almost identical
to GDF-8 in sequence does not regulate muscle growth in vivo
[44]. These unexpected large functional differences between these
highly similar TGF-b members are likely due to non-overlapping
temperospatial expression differences as recombinant GDF-11
can act as a negative regulator of muscle growth by inhibiting dif-
ferentiation of mesenchymal cells into myogenic lineages [45]. But
even for BMP subgroups with overlapping functions such as BMP-
5/-6/-7 individual members of this subgroup might have devel-
oped unique functions in vivo. Besides shared functions with
BMP-5 and BMP-7, BMP-6 is uniquely involved in iron hemostasis
as its mRNA expression is regulated in response to the iron level. As
BMP-6 itself does furthermore stimulate the expression of Hepci-
din, a key regulator of iron absorption, loss of BMP-6 signaling
leads to iron overload as seen in the disease hemochromatosis [46].
The fourth and most heterogeneous subfamily comprises the
distant members of the TGF-b superfamily (Fig. 1A). Based on se-
quence similarity and/or functional properties, GDF-9, BMP-15,
GDF-15 (also known as MIC-1, PLAB, TGF-PL, PDF or PTGFB),
Anti-Muellerian Hormone (AMH), Glial-Derived Neurotrophic Fac-
tor (GDNF) and the related factors Artemin, Neurturin and Perse-
phin fall outside the above described three subfamilies without,
however, forming an own subfamily with a deﬁned relationship.
BMP-15 and GDF-9 are involved in follicle development. Incontrast to GDF-9, BMP-15 is also expressed outside the ovary pos-
sibly indicating additional BMP-15 speciﬁc functions [47]. GDF-15
seems unique showing very low sequence similarity to all other
TGF-bmembers (Fig. 1A). It was identiﬁed by its inhibitory activity
on macrophages arguing for an anti-inﬂammatory function [48]. It
is also strongly expressed in liver, kidney and exocrine glands [49],
but even though GDF-15 expression has been investigated in vari-
ous diseases [50,51], biochemical data on GDF-15 is still sparse
[52]. Interestingly, GDF-15 also has neurotrophic properties (simi-
lar to GDNF). It is expressed in different brain areas and promotes
survival of aminergic neurons under stress and may thus be a po-
tential factor for the treatment of Parkinson’s disease [53]. GDNF
together with Artemin, Persephin and Neurturin forms an own
subgroup and with the latter being the most distant TGF-b subfam-
ily with respect to sequence homology and functions (for review
[54]) (Fig. 1A). GDNF family members are neurotrophic factors
for dopaminergic neurons, which regulate neurite growth, cell size
as well as dopamine uptake. In vitro these factors promote survival
of motoneurons and peripheral neurons. The distant relationship
between the GDNF subgroup and the remaining TGF-b members
also manifests in the usage of a different receptor family (see be-
low, Fig. 1B), with GDNF and its related factors binding to a set
of glycosylphosphatidylinositol (GPI)-anchored membrane pro-
teins and signaling via the receptor tyrosine kinase receptor Ret
[55].
3. Involvement of the prodomain in TGF-b ligand activation
Architecture and sequence motifs indicate that TGF-b ligands
derive from a common ancestor. All members are synthesized
as large dimeric proproteins containing a signal-peptide for secre-
tion and a consensus sequence a so-called cystine-knot motif in
the C-terminus (Figs. 1C, 2A,B). GDNF-related factors differ with
respect to the size of the proprotein part (less than 76 residue
length), which is much smaller compared to other TGF-b mem-
bers (P250 residues). The functional signiﬁcance of the prodo-
main might differ for the individual TGF-b members. It has
been claimed that the prodomain is required for proper folding
and dimerization of the TGF-b ligands, however recombinant
expression of various TGF-bs, BMPs, GDFs and Activins in bacteria
and subsequent refolding of the mature part in vitro suggest that
the propart is not generally required for folding (e.g. [56]). For the
TGF-bs the prodomain (also termed LAP for latency associated
peptide) is an important regulator of factor activation being
non-covalently and tightly attached to the mature part after furin
cleavage. The prodomain confers latency to the TGF-bs and TGF-b
activity requires active removal of the prodomain (Fig. 2C). The
latter is occurring via a complex process at the cell surface involv-
ing binding of the proprotein to extracellular matrix components,
LAP binding proteins such as av integrins and LTBP (Latent TGF-b
Binding Protein) to ﬁnally strip off the prodomain by tensile
forces [57]. Recent structure analysis of latent TGF-b1 now pro-
vides insight how latency is generated [58]. The interaction of
the prodomain-mature part resembles a ‘‘straitjacket’’ with the
prodomain covering all receptor epitopes of TGF-b1 thereby
blocking receptor binding (Fig. 2A,B). Only few other TGF-bs are
also latent, e.g. GDF-8 and -11 [59,60]. Others like BMP-4, -7,
-9, -10 or GDF-5 remain associated with their prodomains after
secretion, but do no exhibit a similar latency effect as TGF-bs
[61]. The different biological function of the prodomain might
be explained by the amino acid sequence variability, which is
much larger in the prodomains than in the mature part of TGF-
bs. In TGF-b1/2/3 the prodomain itself forms an obligate
disulﬁde-linked dimer (Figs. 1B, 2A), which likely attaches to
the mature region with higher afﬁnity due to avidity effects.
Fig. 2. (A) Ribbon representation of the TGF-b1 pro-protein. The mature part of TGF-b1 is highlighted in green and cyan; the pro-region can be separated into the Arm domain
and the ‘‘straitjacket’’. The Arm domain comprises binding sites for Vb6 integrins required for activation of the TGF-bs. In case of the TGF-bs, the ‘‘bowtie’’, which is important
for dimer formation of the pro-part, contains four cysteine residues involved in intermolecular disulﬁde bonds stabilizing the pro-part dimer. The ‘‘straitjacket’’ blocks ligand–
receptor interaction by blocking access to the type I receptor epitope through the N-terminal helix (1, marked in orange) as well as to the type II receptor site through the so-
called latency lasso (2, marked in red). For other TGF-b ligands the helix 2 (3, indicated in magenta) blocks binding of type II receptors to the ligand. (B) As in (A) but rotated
around the x-axis by 90 to highlight blocking of type I and type II receptor binding sites (indicated by boxes). (C) Release of the mature TGF-b ligand from the pro-protein
complex is realized by tensile forces through binding of the N-terminus of pro-TGF-b1 to LTBP (Latent TGF-b binding protein) and interaction of Vb6 integrins with the RGD-
motif in the Arm domain. (D) For TGF-b ligands the pro-protein might also exhibit an elevated solubility under physiological conditions by shielding the hydrophobic receptor
epitopes (indicated by boxes). (E) The mature region of TGF-b1 shows large, solvent accessible (conserved) hydrophobic patches (indicated by boxes), which coincide with the
wrist and knuckle epitopes of BMPs.
T.D. Mueller, J. Nickel / FEBS Letters 586 (2012) 1846–1859 1849The cysteines forming these interchain disulﬁde bonds are lacking
or positioned differently in other TGF-b members. In addition the
region involved in prodomain dimerization shows very little se-
quence conservation arguing for a less stable dimer formation
of the prodomain [58]. Hence the prodomains of other TGF-b li-
gands than TGF-b1/2/3 likely bind as ‘‘monomers’’ and can thus
be more easily displaced. A common prodomain feature, however,
might be the solubility enhancement through the formation of a
non-covalent prodomain-mature TGF-b complex. Biochemical
studies have shown that the mature regions of TGF-b ligands
alone exhibit poor solubility under physiological conditions due
to large hydrophobic surface patches, whereas the proprotein
complex is sufﬁciently soluble to allow transport by diffusion
and thus might be required for other than paracrine activities
(Fig. 2D,E) [62].4. Cystine-knot architecture of TGF-b members
The key feature of the mature part of all TGF-b members is the
10-membered cystine-knot, which consists of four cysteine resi-
dues with the spacing Cys2-X-Gly-X-Cys3 and Cys5-X-Cys6 forming
a ring structure (Fig. 3A–C). A third disulﬁde bond formed between
the ﬁrst and the fourth cysteine penetrates the ring structure
thereby tying the knot (Fig. 3C). The cystine-knot architecture is
not limited to the TGF-b superfamily and is also found in other
growth factor families, but the consensus motif for TGF-bmembers
is characterized by a stop codon one amino acid after the last cys-
teine residue [63]. The restriction to only one amino acid following
the last cysteine residue is easily explained by the structures of the
TGF-b ligands, which show a butterﬂy-shaped dimer arrangement
with the C-termini locked up in-between the dimer interface.
Fig. 3. (A) Ribbon representation of BMP-2. The butterﬂy-shaped architecture of the dimeric ligand resembles two hands assembled palm-to-palm, with the b-sheets
representing ﬁngers 1 and 2, the -helix and the dimer interface forming the palm, and the N-terminus described as thumb. The convex side of the ﬁngers termed knuckle
epitope is the binding interface for type II receptors in the BMP/GDF and Activin subgroups, TGF-bs bind their type II receptors at the ﬁnger tips. Type I receptor binding occurs
in the so-called wrist epitope formed by the concave side of the ﬁngers and the palm of the ligand. (B) As in (A) but viewed along the ligand’s two-fold symmetry axis. (C)
Close-up of the cystine-knot, which is formed by two disulﬁde bridges between Cys2-Cys5 and Cys3-Cys6 building a ring-like structure, and a third disulﬁde bond between
Cys1 and Cys4 penetrating this ring. (D) Schematic representation of the TGF-b/BMP signaling cascade. Upon binding of the TGF-b ligand to its type I and type II receptors (1),
the type II receptor transphosphorylates the type I receptor at the GS-box (marked by a red square), thereby activating the type I receptor kinase. Transmembrane or
membrane-associated co-receptors (2) can modulate the ligand–receptor speciﬁcity or enhance binding afﬁnity of individual TGF-b receptors. Modulator proteins (3) or
pseudo-receptors (3) can impede receptor activation by either blocking the ligand or the receptors. The classical SMAD pathway is activated by phosphorylation of R-SMAD
factors by the type I receptor kinase leading to complex formation between the R-SMADs and the Co-SMAD SMAD4 (4). The latter complex can translocate into the nucleus
and (together with other transcription factors possibly activated by other signaling pathways) regulate gene transcription. So-called inhibitory or I-SMADs can interfere with
SMAD signaling by forming inactive complexes with SMAD4 (5). Besides the canonical SMAD pathway, other signaling cascades (either SMAD independent or connected to
SMAD proteins at different points) have been described for TGF-b/BMP signaling. For instance, LIMK kinases have been shown to associate with BMP receptors (or being
regulated by TGF-b receptors), thereby modulating actin polymerization (6). The PI3 kinase was described to interact directly with TGF-b receptors, thereby relating TGF-b
and Akt signaling (7). The anti-apoptotic protein XIAP also binds to TGF-b receptors resulting in the recruitment of the TGF-b-activated protein kinase TAK1 (8). This complex
leads to activation of the MAP kinase pathway (p38 and JNK kinases), which have been shown to encode for apoptosis signals by TGF-b/BMPs.
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T.D. Mueller, J. Nickel / FEBS Letters 586 (2012) 1846–1859 1851Adding further residues to the C-terminus would disrupt this
dimer architecture and thus explains the observation that adding
peptide sequence tags to the C-termini usually inactivates TGF-b
ligands. Most TGF-b ligands (except Lefty-1/-2, GDF-3, GDF-9 and
BMP-15) have a Cys residue just ahead of the fourth cysteine of
the cystine-knot, which forms an intermolecular disulﬁde bond
stabilizing the ligand dimer (Figs. 1C, 3A–C). Although the TGF-b
ligand members are considered homodimeric, the similarity in
amino acid sequence and architecture has led to the proposal of
heterodimeric TGF-b ligands with unique functions. Despite such
heterodimers, e.g. BMP-2/6 or BMP-4/7 can be produced recombi-
nantly in prokaryotic and eukaryotic expression systems [64,65],
evidence for the in vivo existence of BMP heterodimers is so far
only available for zebraﬁsh [66] or ﬂy [67,68], but not for mammals
[69]. One possible reason against arbitrary heterodimer formation
might be the sequence variability in the regions responsible for
prodomain dimerization. In contrast to the high sequence similar-
ity seen in the mature region this region (called ‘‘bowtie’’ in [58],
see Fig. 2A) displays high variability and thus may limit or destabi-
lize heterodimer formation.
5. TGF-b receptor assembly and downstream signaling
TGF- ligands transduce their signal via binding to two different
subtypes of transmembrane serine-/threonine kinase receptors
termed type I and type II (Fig. 1B,D). Although the two receptor
subtypes also show differences in extracellular ligand-binding do-
mains [5], the presence of a membrane-proximal glycine/serine-
rich segment called GS-box present only in type I receptors is used
for classiﬁcation (Fig. 1D). Due to their nature as single span trans-
membrane receptors it is assumed that mechanistically ligand-in-
duced assembly of type I and type II receptors is the trigger for
downstream signaling (Fig. 3D). As TGF-b ligands are dimers, two
receptors of either subtype assemble in a heterotetrameric recep-
tor complex. Besides the classical ligand-induced receptor-oligo-
merization also ligand-induced activation of preformed receptor
assemblies was described, with the two mechanism potentially
activating different signaling cascades [70]. Subsequent phosphor-
ylation of the type I receptor kinase by the type II receptor kinase
leads to activation of the former, which then can phosphorylate
and activate SMAD proteins. SMAD proteins are transcription fac-
tors that upon phosphorylation hetero-oligomerize, translocate
into the nucleus and together with transcriptional co-activators
or co-repressors regulate transcription of responsive genes. There
are two sets of SMAD proteins (also termed R-SMAD for recep-
tor-regulated SMAD) that interact and become phosphorylated
by the type I receptors (Figs. 1A,B and 3D). Structural and func-
tional studies have revealed that a cytoplasmic loop segment
(called L45 loop) close to the GS-box of the type I receptor and a
corresponding loop segment in the SMAD protein (called L3 loop)
determines the speciﬁcity, which set of SMAD proteins are sub-
strates for the respective type I receptor kinase [71,72]. The SMAD
proteins SMAD 1, 5 and 8 are substrates of type I receptors usually
engaged by members of the BMP/GDF-subgroup, whereas SMAD 2
and 3 are typically activated by type I receptors triggered by TGF-
bs, Activins and Nodal (Fig. 1A,B). Upon phosphorylation the R-
SMAD proteins assemble with the so-called Co-SMAD 4 forming
a heterotrimer required for nuclear translocation [73]. Two further
SMAD proteins SMAD 6 and 7 (I-SMAD for inhibitory SMAD) can
impede phosphorylation of R-SMADs hereby negatively regulating
SMAD activation (Fig. 3D). All R-SMADs recognize the DNA-se-
quence CAGA but bind this sequence only with low afﬁnity [74],
additional motifs, usually targeted by partner co-factors, are re-
quired to obtain sufﬁcient binding afﬁnity for transcriptional regu-
lation, but also to acquire cell-type speciﬁc selectivity for targetgenes (for review [6,75]). Thus the cell-type speciﬁc presence or
absence of these SMAD co-factors or a coupling of the TGF-b SMAD
pathway to other signaling pathways, which provide (or activate)
the proper co-factors, can then enable transcriptional regulation
of a cell-type speciﬁc set of target genes speciﬁc for a particular
TGF-b member. Such coupling or cross-talk has been reported for
several growth factor-signaling pathways, e.g. the Wnt/b-catenin,
the LIF, or the TNF- pathway (for review [76]). Besides this cross-
talk between different signaling factors also non-SMAD or SMAD-
independent signaling pathways directly emanating from TGF-b
receptors were postulated in particular involvement of MAP kinase
pathways [77] (Fig. 3D). For instance, the regulatory subunit p85 of
the phosphoinositide 3-kinase (PI3K) associates with the TGF-b
receptor. The regulatory subunit p85 then activates PI3L in a li-
gand-dependent manner thereby linking the PI3K/Akt pathway to
TGF-bs [78]. Similarly, BMP receptors can form complexes with
the intracellular TGF-b-activated kinase 1 (TAK1) through the
binding partners TAB1 and the ubiquitin E3 ligase XIAP, which is
an inhibitor of apoptotic caspases. This leads to activation of the
p38 kinase and shows that responses can be induced via SMAD-
independent signaling pathways [79] (Fig. 3D). A recent review
summarizes the results of ongoing research trying to identify addi-
tional components associating with the cytoplasmic domains of
TGF-b receptors and known TGF-b signaling components [80].
The multitude of interaction partners already found so far suggests
that the intracellular TGF-b signaling resembles more a large
entangled signaling network rather than a linear cascade.
6. Many ligands – too few receptors
In contrast to the number of TGF-b ligands, which increased
dramatically during evolution, the number of available type I and
type II receptors seems amazingly low, particularly when assuming
a mechanism such as one factor – one receptor – one function
(Fig. 1A,B). In worm ﬁve potential ligands face two type I and
one type II receptors, in ﬂy the seven TGF-b members signal via
three type I and two type II, but in humans only seven type I and
ﬁve type II receptors have to sufﬁce for the more than 30 TGF-b li-
gands [6,81]. This numeral discrepancy between the number of
TGF-b ligands and available receptors immediately implies that a
particular receptor of either subtype has to bind more than one li-
gand. In very few cases usage of a receptor seems conﬁned to one
TGF-b subfamily or even a single TGF-b ligand. Only the Anti-
Muellerian Hormone (AMH) type II receptor (AMHR-II) is solely
activated by AMH [82]. The TGF-b type II receptor (TbR-II) only
binds to the three isoforms TGF-b1, -b2, and -b3 but no other
TGF-b superfamily members (Fig. 1A). All other type I and type II
receptors are shared among ligands of one subfamily or even are
used by members from different subfamilies [83]. Among the type
II receptors the Activin type II receptors ActR-II and ActR-IIB are
most widely utilized (Fig. 1A). This is of special interest as ActR-II
and ActR-IIB exhibit a dual signaling speciﬁcity [84]. By binding
to members of the Activin subfamily (or GDF-8/GDF-11) the Acti-
vin type II receptors are involved in activation of the SMAD 2/3
pathway whereas binding to members of the BMP/GDF subfamily
results in activation of SMAD 1/5/8. Some opposing activities of
Activin-A and BMPs might be thus explained with competing bind-
ing to the Activin type II receptors [85]. Therefore one receptor can
participate in different signaling complexes leading to distinct
SMAD responses.
But we do not only see receptors binding various ligands from
one or more TGF-b subfamilies, usually a particular TGF-b ligand
can also bind to several TGF-b receptors of either subtype. This
phenomenon called ligand–receptor promiscuity is particularly
(but not exclusively) present in the BMP/GDF subfamily. In vitro
1852 T.D. Mueller, J. Nickel / FEBS Letters 586 (2012) 1846–1859binding analyses show that the three type II receptors BMPR-II,
ActR-II and ActR-IIB interact similarly with any member of the
BMP-2/4, BMP-5/6/7 and the GDF-5/6/7 subgroup (Fig. 1A). Even
binding of Activin-A to either Activin type II or the BMP type II
receptor in vitro differs only by a factor of 10 in afﬁnity [86]. Chem-
ical crosslinking experiments, biophysical in vitro analyses or func-
tional studies employing receptor overexpression in cells suggest
that BMP/GDF ligands from the GDF-1/-3 [87], the BMP-3/GDF-
10 [88] or the GDF-8/-11 [89] subgroup are more selective, binding
speciﬁcally to the Activin type IIB receptor (ActR-IIB). Instead, sev-
eral TGF-b ligands from different subfamilies such as members of
the GDF-9/BMP-15 subgroup [90,91] or BMP-9 [92] exhibit strong
preference for BMPR-II. But not only type II receptors are widely
shared between different TGF-b ligands also type I receptors, which
restrict the downstream SMAD pathway are jointly used (Fig. 1A).
Members of the BMP-2/4, BMP-5/6/7 and GDF-5/6/7 subgroup and
also AMH bind to the type I receptors BMPR-IA (ALK3) and BMPR-
IB (ALK6) although with variable afﬁnities [86]. The type I receptor
ActR-I (ALK2) is also bound by members of the BMP-5/6/7 sub-
group besides BMPR-IA and BMPR-IB. But in vitro interaction anal-
yses reveal that its binding afﬁnity to BMP-6 and BMP-7 is the
lowest among the type I receptors recognized [86]. Surprisingly,
cell-based experiments using deglycosylated BMP-6 speciﬁcally
deﬁcient in binding to ActR-I (ALK2) suggest that ActR-I is never-
theless essential as signaling type I receptor for the BMP-5/6/7 sub-
group. Here, BMPR-IA cannot replace ActR-I (e.g. in C2C12 cells)
despite exhibiting a 15 to 20fold higher in vitro binding afﬁnity
compared to ActR-I [93]. The Activin type I receptor ActR-IB
(ALK4) is probably the most promiscuous type I receptor for mem-
bers (BMP-3, GDF-1/3, Activin/Nodal, GDF-8/11) activating the
SMAD 2/3 pathway [87,94–97]. For some ligands the co-receptor
Cripto is required for binding to ActR-IB (ALK4) [87,96]. Other
TGF-b superfamily ligands besides TGFb1/2/3, i.e. GDF-8 or GDF-
9, also bind the TGF-b type I receptor TbR-I (ALK5) showing that
even this type I receptor is not limited to a particular ligand sub-
family [97,98] (Fig. 1A). The TGF-b receptor ActR-IC (ALK7) has ini-
tially been identiﬁed as orphan receptor, but now serves as an
alternative type I receptor for Nodal [96], furthermore certain Acti-
vin isoforms can also use ActR-IC [99]. The TGF-b superfamily
receptor type I (TSR-I or ALK1) is a highly interesting member, as
very few interacting ligands have been identiﬁed so far. Whereas
BMP-9 has been shown to interact with TSR-1 with high afﬁnity
[92], TSR-I can also serve as an alternative type I receptor for
TGF-b1/2/3 [100] (Fig. 1A). So far all ligand-type I receptor combi-
nations were strictly restrained to a single SMAD pathway, either
1/5/8 or 2/3, even when a ligand exhibits promiscuous binding to
various type I receptors. The usage of TSR-1 by TGF-b1/2/3 and
the subsequent activation of the SMAD 1/5/8 pathways breaks this
rule, showing that a TGF-b ligand depending on the cellular context
can induce both otherwise strictly separated pathways (Fig. 1A).
Although the above-described scenario immediately implies a
highly promiscuous interaction network between different ligands
and a limited set of receptors, one has to be cautious in interpreting
the available data for the ligand–receptor promiscuity. Whereas
biophysical interaction analyses such as surface plasmon reso-
nance might provide for very accurate afﬁnity data these measure-
ments might not reﬂect the situation in organisms, as it needs to be
combined with expression data to ﬁnd in vivo examples where
such combinations of promiscuous ligands and receptors are pres-
ent at the same place and time. Similarly, ligand–receptor interac-
tion analysis using chemical crosslinking data on cells also usually
use recombinant factors as probes neglecting temporospatial
expression of the binding partners analyzed and the crosslinking
might also dependent on ligand/receptor reactivity. However, that
the pronounced ligand–receptor promiscuity in the TGF-b super-
family might indeed affect TGF-b/BMP signaling also in vivo canbe deduced from various studies analyzing the development pro-
cesses. For instance studies of limb development [34] have shown
that different BMP ligands with overlapping receptor usage act in a
spatially and timely highly conﬁned space and thus ligand–recep-
tor promiscuity is likely to occur during this process.7. A different assembly explains high ligand–receptor speciﬁcity
for TGF-b1/2/3
This highly interweaved and complex ligand–receptor network
raises two immediate questions. First, what is the molecular basis
for this promiscuous ligand–receptor interaction considering se-
quence identity of sometimes less than 30% between receptor-
sharing TGF-b ligands? Structure analyses have revealed a highly
conserved butterﬂy-shaped dimer structure for the mature region
of TGF-b ligands (Fig. 3A,B). The architecture resembles two hands
(one for each monomer) assembled palm-to-palm, the b-sheets are
described as ﬁngers, the -helix and the dimer interface forming the
palm, and the N-terminus resembling the thumb (for review [81]).
Mutagenesis studies as well as structures of TGF-b ligand–receptor
complexes clearly show that promiscuous receptor binding is not
achieved by using different epitopes for each combination [101–
105]. Activins and BMP/GDF ligand members all seem to bind their
type II receptors via the so-called knuckle epitopes (back side of
the ﬁngers), whereas type I receptor binding occurs in the wrist
epitope, which is formed by the front side of the ﬁngers and the
palm of the TGF-b ligand [106] (Figs. 3B, 4A,B). Only the TGF-b1/
2/3 are exceptions, with the type II receptor TbR-II binding to their
ﬁnger tips (Fig. 4D,E), differences in the afﬁnities of the three TGF-b
isoforms to TbR-II are due to amino acid differences in the ﬁnger-
tips [107]. Comparing the structures of the ternary complexes of
TGF-b3:TbR-I:TbR-II and BMP-2:BMPR-IA:ActR-IIB shows that the
high speciﬁcity for the TGF-bs – type II receptor interaction is
due to differences in length and conformation of the ﬁnger tips
in TGF-bs allowing only binding of TbR-II to TGF-bs but not to
BMPs. Binding of TbR-II to other BMP/GDF ligands is impeded by
the structural differences clearly separating TbR-II from the other
type II receptors ActR-II, ActR-IIB and BMPR-II. Furthermore, sev-
eral amino acid differences in the region equivalent to BMP-2’s
knuckle epitope prevent binding of the type II receptors ActR-II,
ActR-IIB or BMPR-II to TGF-bs. Most evident, residue Ala34 in the
knuckle epitope of BMP-2, which yields an antagonist upon A34D
mutation [106], is occupied by a conserved glutamate residue in
all three TGF-b isoforms. Also the position and orientation of the
type I receptor TbR-I differs in the ternary complex TGF-b3:TbR-
I:TbR-II from that found for the type I receptor in structures of
BMP and GDF ligand–receptor complexes (Fig. 4A-E). The ectodo-
main of TbR-I is shifted towards the ﬁngertips of TGF-b3 and the
type I receptor binding is mediated by direct contacts between
TbR-I and TbR-II (Fig. 4E,F). Such receptor–receptor contacts are
absent in BMP ligand–receptor complexes explaining the non-
cooperative binding for BMPs (Fig. 4C). Consequently, the highly
cooperative binding of TbR-I in the TGF-b ligand–receptor complex
formation requires the prior presence (or complex formation) of
TGF-bs with TbR-II to allow type I receptor binding, which raises
the question how TbR-I binds to GDF-8 or GDF-9, which associate
with ActR-IIB via the classical knuckle epitope as seen for Activin-A
[105]. Despite that structure analysis of GDF-8 bound to the mod-
ulator Follistatin [108] shows that the so-called pre-helix loop (see
also Fig. 3B), an important element for type I receptor speciﬁcity in
BMP ligand–receptor interactions [109–111], adopts a TGF-b like
conformation and thus should enable TbR-I binding to GDF-8, the
different position of type I and type II receptor will disrupt direct
receptor–receptor interface essential for TGF-b receptor complex
formation.
Fig. 4. (A) Structure of the ternary complex of BMP-2 bound to the extracellular domains of BMPR-IA and ActR-IIB. The two ActR-IIB receptors bind to the knuckle epitope of
each monomer, whereas the two BMPR-IA receptors interact with the wrist epitopes. (B) As in A) but rotated around the x-axis by 90. (C) In contrast to TGF-b3 ligand–
receptor interaction, no direct contacts exist between the extracellular domains of the type I and type II receptors in BMP ligand–receptor complexes. (D) Structure of the
ternary complex of TGF-b3 bound to the extracellular domains of TbR-I and TbR-II. (E) As in (D) but rotated around the x-axis by 90. The type II receptor ectodomains interact
with the tips of ﬁngers 1 and 2 of each TGF-b3 monomer. The TbR-I receptor binds to the wrist epitope, but its orientation and location is slightly shifted compared to BMP
ligand–receptor complexes. This results in direct contacts between the N-termini of the type I and type II receptors explaining the cooperative binding observed for the TGF-b
ligand–receptor interaction (marked by arrows). (F) Cooperative binding of the TbR-I is due to a direct interaction between the TbR-I N-terminus and TbR-II (shown as
magenta van-der-Waals surface).
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As the location of the receptor binding epitopes in Activin and
BMP/GDF ligands are the same (Fig. 3A,B), other mechanisms such
as different amino acid motifs must exist to ensure type I and type
II receptor selectivity if required. In particular the type II receptors
ActR-IIB and ActR-II are highly promiscuous and bind to many dif-
ferent Activin and BMP/GDF ligands. Several structures of com-
plexes of different ligands (BMP-2, BMP-7 and Activin-A) bound
to either ActR-II or ActR-IIB provide insight into promiscuity and
speciﬁcity of the type II Activin receptors [101,102,105,112,113].
Mutagenesis has established the functional epitope of BMP-2 to
BMPR-II and ActR-II showing that the type II receptor epitope is
dominated by hydrophobic interactions [106], which has been con-
ﬁrmed also by the above-mentioned structural studies. However,
of 24 residues of BMP-2 forming the interface mutagenesis has
only found six to signiﬁcantly inﬂuence type II receptor binding
[106], with only one position (Leu90 in BMP-2) being absolutely
conserved among all Activin type II receptor binding ligands
(Fig. 5A).
This lack of a highly conserved interface between ligands and
their shared receptors ActR-II and ActR-IIB might on the one hand
be explained by the concept of so-called hot spot of binding intro-
duced by James Wells in 1995 [114] (Fig. 5B,C). Herein, the resi-
dues in the center of a protein–protein interface contribute the
majority of the overall binding energy of an interaction, whereas
surrounding residues provide sealing from the environment. Thus
the central residues are usually conserved, whereas peripheral
amino acid residues can be exchanged as long as their sealing func-
tion is maintained (Fig. 5A–C). More than one hot spot can exist via
modular interfaces and by combining different hot spots of binding
a scalable afﬁnity can be achieved [115]. The latter seems also to
apply for the Activin type II receptor interactions. Whereas BMP-
2 (and other BMPs and GDFs from the BMP-5/6/7 and GDF-5/6/7
subgroup) binds ActR-II and ActR-IIB with rather low micromolar
afﬁnities, binding of these receptors by Activins occurs with very
high afﬁnity in the nanomolar range [86]. There is evidence(although pull down experiments provide only semi-quantitative
data) that all TGF-b ligands binding to SMAD 2/3 activating type
I receptors seem to exhibit high afﬁnities for their type II recep-
tor(s), and BMPs and GDFs activating the SMAD 1/5/8 pathway
bind rather their type I receptors with high afﬁnities. Whether this
is a general mechanism that possibly also inﬂuences signal trans-
duction and further discriminates the SMAD 1/5/8 and SMAD 2/3
pathways remains to be resolved by further quantitative functional
analyses.
The search for the type II receptor afﬁnity difference between
BMPs and Activins revealed that indeed a second hot spot of bind-
ing exists in the ligand-type II receptor interface. Sequence and
structure comparisons of the Activin-A:ActR-II and the BMP-
2:ActR-IIB interactions showed that only two residues differing be-
tween BMP2 and Activin-A can switch a low-afﬁnity to a high-
afﬁnity epitope [101] (Fig. 5D,E). Mutation of Leu100 and Asn102
in BMP-2 to the equivalent amino acids Lys and Asp in Activin-A
enhances the afﬁnity by shielding a hydrogen bond between
Ser88 of BMP-2 and a backbone amide in the ActR-IIB receptor
from the environment (Fig. 5D,E). Thus a high-afﬁnity epitope to
ActR-IIB might consist of the general hydrophobic hot spot of bind-
ing (which is centered around Ala34 and Leu90 in BMP-2) used by
all Activin and BMP type II receptors [101,116]. It is remarkable
that the ‘‘shielding’’ residues (equivalent to Leu100 and Asn102
in BMP-2) show indeed little variation with respect to their side
chain size showing larger side chains at the ﬁrst and second posi-
tion for most ligands with assumed high afﬁnity for ActR-IIB. As
the afﬁnity differences mediated by the exchanges at these two
positions were quite speciﬁc for ActR-IIB and did not affect interac-
tion of ActR-II (nor BMPR-II) with BMP-2 (Fig. 5D,E), speciﬁcities
for the type II receptors might be achieved through the use of dis-
tinct additional hot spots. Further mutations in BMP-2 provided
two other positions speciﬁcally modulating the afﬁnity for
BMPR-II [101], and a structure-/function study showed that the
high ActR-IIB speciﬁcity of BMP-3 is due to a charge–charge pair
involving a lysine residue to BMP-3 (Lys30) and a glutamate in
ActR-IIB (Glu76), which is a lysine in ActR-II [88]. Interestingly,
Fig. 5. (A) The hotspot of binding in BMP-2 for the BMP type II receptor interaction consists of a hydrophobic patch formed by two residues (Leu90 and Leu100, marked in
red) located in the center of the large type II receptor contact area (marked in dark gray). A nearby second hot spot of binding mediated by a hydrogen bond (shown in green)
is activated in the high-afﬁnity Activin-A type II receptor interaction. (B) A hot spot of binding usually consists of a central bond (marked in red), which is either a polar
(hydrogen bond) or hydrophobic interaction, which is then shielded from the environment by a shell of complementary (hydrophobic or polar, respectively) residues. (C)
Shared interaction components that interact with their different binding partners with variable afﬁnities often contain several hot spot of bindings, some of which are used
for low afﬁnity binding and all of them together can enforce high afﬁnity binding. (D) Low-afﬁnity binding of BMP ligands to the Activin type IIB receptor only utilizes the
hydrophobic patch. (E) ‘‘Activation’’ of the second hotspot by mutating two ‘‘shielding’’ residues (L100K, N102D) in close proximity confers high afﬁnity binding of BMP-2
(BMP-2KD) to ActR-IIB. The additional binding afﬁnity is not due to direct ligand–receptor interactions via the two mutated residues, but due to protection of the hydrogen
bond between the hydroxyl group of the conserved serine (Ser88 in BMP-2) and a main chain amide of the type II receptor (Leu61). The amino acid replacements block water
from accessing the central hydrogen bond thereby increasing its contribution to the binding energy.
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ligands, e.g. Nodal, GDF-8, GDF-11, which are reported to use ActR-
IIB as their high afﬁnity receptor. The hot spot of binding mecha-
nism is not limited to the ligand-type II receptor interface but is
also found in the BMP-2 interaction with their high afﬁnity type I
receptors BMPR-IA (ALK3) and BMPR-IB (ALK6). Alanine scanning
mutagenesis did ﬁrst not reveal residues altering binding afﬁnity
by more than factor of 10 [106]. A reﬁned structure-/function anal-
ysis then revealed that a conserved hydrogen bond pair in the BMP
type I receptor interface is the hot spot and that the surrounding
residues mainly shield this polar interaction from destabilizing ac-
cess of solvent [109].
The concept of hot spots of binding together with the likely
combinatorial use of a modular interface with several potential
hot spots possibly forms the basis of promiscuous type II receptor
binding by Activin and BMP/GDF ligands with the concurrent capa-
bility to scale afﬁnity by more than 50fold (Fig. 5B,C). This imple-
mentation possibly also explains the structural variability of the
plethora of extracellular antagonist, modulator proteins, or co-
receptors identiﬁed for the ligands of the TGF-b superfamily
(Fig. 6A–H). Structures of several of these modulator protein–
TGF-b ligand complexes have been determined in the past, e.g.
BMP-7:Noggin (Fig. 6B,F) [117], Follistatin bound to Activin or
GDF-8 (Fig. 6C,G) [108,118,119], or of the Chordin-related ﬁrst
Von Willebrand type C (VWC1) domain of Crossveinless-2 (CV2)
bound to BMP-2 (Fig. 6D,H) [120]. None of the three examples of
modulator proteins share any structural similarity; nevertheless
all bind to the same epitopes also used by type I and type II recep-
tors of the TGF-b superfamily (Fig. 6). Functional studies employing
mutagenesis show that even though the Von Willebrand domain
and the BMP type II receptors are structurally completely distinct,
the same hot spots, e.g. Leu100 in BMP-2, are used for binding
[120]. Thus, the need of only a few conserved residue pairings with
a (large) group of variable surrounding residues to shield and
maintain the core interaction will allow the development of struc-
turally highly different interaction partners.
9. Structural ﬂexibility and adaptability
Besides the hot spot of binding mechanism inherent structural
ﬂexibility of TGF-b ligands and their receptors has been identiﬁed
as a possible source to modulate ligand–receptor speciﬁcity. Struc-ture analyses of ‘‘free’’ type I and type II receptors have indicated
that the receptor ectodomain can perform an induced ﬁt mecha-
nism of variable degree upon binding to the ligand (Fig. 7A–C).
For the type II receptors crystal structures of ActR-II and BMPR-II
in their unbound form reveal that the core ligand-binding interface
is preformed and only peripheral loops undergo conformational
rearrangement upon complex formation [121,122]. In contrast,
NMR structure analysis of the BMP type I receptor BMPR-IA
showed that the majority of its ligand-binding interface is unstruc-
tured and highly dynamic [123]. Upon binding to BMP-2 a 15mer
loop passes through a disorder-to-order transition folding into a
highly deﬁned segment with a 1.5-turn helix in the center
(Fig. 7A,B). Most interestingly, this segment holds the hot spot of
binding of BMPR-IA for recognizing and binding to BMP-2 indicat-
ing that a ﬁxation or pre-orientation of the residue(s) serving as
hot spot of binding is not required. That the ﬂexibility of the loop
segment in BMPR-IA can really serve to adapt to different geome-
tries and thus might potentially enhance binding partner diversity
was conﬁrmed from structure analysis of the BMPR-IA ectodomain
bound to the neutralizing antibody raised against BMPR-IA
(Fig. 7C) [124]. Here, the antibody as well as the physiological li-
gand BMP-2 bind to the very same epitope of the common partner
BMPR-IA but induce vastly different conformations in the ﬂexible
segment. Thus the ﬂexibility seen in the ligand binding epitope
of BMPR-IA might be utilized for interface adaptation during bind-
ing of different ligands although the structural similarity of BMPR-
IA-recognizing BMP ligands will require a much smaller conforma-
tional adaptation compared to the antibody. A ﬂexible recognition
segment is not a common motif in all type I receptors of the TGF-b
superfamily, as structure analysis of TbR-I shows that here the
equivalent region is structured and rigid by introducing proline
residues and the pre-ordered structure is essential for TGF-b bind-
ing and speciﬁcity [125]. Another example in which ﬂexibility is
used to create speciﬁcity is the type I receptor speciﬁcity of GDF-
5 (Fig. 7D,E). Studies of knockout mice suggest that GDF-5 signal-
ing through the BMP type I receptor BMPR-IB (ALK6) is important
for correct GDF-5 function [34,126]. Although chemical crosslink-
ing of GDF-5 could only be detected to BMPR-IB suggesting an
exclusive interaction [127], in vitro binding analyses show that
GDF-5 binds to BMPR-IB with only a 10 to 15-fold higher afﬁnity
than to BMPR-IA [86,110]. A single residue could be identiﬁed in
GDF-5, Arg57 located in the wrist (type I receptor binding) epitope,
Fig. 6. (A–D) The concept of hot spot of binding, which requires little sequence conservation in large protein–protein epitopes possibly explains the structural variability of
knuckle–epitope interacting binding partners of BMP/GDF ligands. A comparison of the complexes of BMP-2 – ActR-IIB (A), BMP-7:Noggin (B), GDF-8:Follistatin (C) and BMP-
2:Van Willebrand domain (D) (BMP-2:VWC1 of Crossveinless 2) reveals no structural similarities between the different BMP binding partners, which nevertheless bind to the
same epitope of the BMP/GDF ligands. Red regions interact with the type II receptor epitope, green regions interact with the type I receptor epitope, yellow regions either do
not contribute to binding or constitute additional linker domains. (E–H) Close-up of the interactions between the BMP knuckle epitope (marked in purple) and the receptor (E,
ActR-IIB) or the modulator proteins (Noggin (E), Follistatin (F), or the Von Willebrand domain 1 of the BMP modulator protein Crossveinless 2 (G)). All of these binding
partners show the overlapping (promiscuous) binding to various ligands of the BMP and GDF subgroup.
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of this residue in GDF-5 to alanine, the equivalent amino acid in
BMP-2, leads to a complete loss of discrimination between
BMPR-IA and BMPR-IB and results in a GDF-5 variant R57A, which
exhibits BMP-2 like binding characteristics [110]. A similar muta-
tion R57L is also found in patients suffering from the skeletal mal-
formation disease symphalangism and shows that type I receptor
speciﬁcity is essential for proper GDF-5 signaling [128]. Structure
analysis of the GDF-5:BMPR-IB complex now show that a receptor
loop segment, which contacts Arg57 in GDF-5 exists in two differ-
ent conformations in BMPR-IB and BMPR-IA (Fig. 7D,E) [111].
Whereas in BMPR-IB the loop adopts a conformation providing suf-
ﬁcient space for the bulky arginine side chain, the loop conforma-
tion found in BMPR-IA would result in steric hindrance, thereby
explaining the lower binding afﬁnity of GDF-5 to BMPR-IA
(Fig. 7E indicated by a red circle). Interestingly, the speciﬁcity-
determining bulky residue arginine is conserved in all BMPR-IB
speciﬁc TGF-b ligands, i.e. GDF-5, -6, -7 and BMP-15.
Another form of possibly creating type I receptor speciﬁcity is
seen for TGF-b2 and Activin-A. Structures of the binary complexes
bound to their type II receptors TbR-II and ActR-II present TGF-b li-
gands deviating from the canonical butterﬂy-shaped dimer archi-
tecture (Fig. 7F–H) [113,129]. The dramatic opening of the TGF-
b3 dimer (Fig. 7F) but also the wing beat motion of Activin-A
(Fig. 7G,H) completely disrupt the type I receptor epitope, but
the canonical dimer architecture would be formed upon ‘‘ﬁxing’’
the ligand via binding to two type II receptors on the cell surface
[113]. NMR relaxation studies show that the dimer interface of free
TGF-b3 is indeed destabilized and would thus be consistent with
such a limited unfolding of the ligand dimer [130]. One might ar-
gue that this change in dimer architecture might be important
for type I receptor speciﬁcity as the disrupted type I receptor epi-
tope is unable to bind BMP type I receptors such BMPR-IA,
BMPR-IB or ActR-I (ALK2). However, once the canonical butterﬂy
dimer architecture is formed other mechanism must ensure dis-
crimination between the different type I receptors and thus this
reasoning seems unlikely. One other explanation might be the
establishment of a stepwise sequence of receptor binding such that
ﬁrst type II receptor binding occurs through the unaffected epi-topes leading to subsequent formation of the type I receptor epi-
topes by constraining the ligand ﬂexibility and allowing type I
receptor binding only as the second step.
10. Ligand–receptor promiscuity versus functional speciﬁcity
Despite our knowledge of how promiscuity and speciﬁcity can
be generated, one important question resulting from the pro-
nounced promiscuity in TGF-b ligand–receptor interaction remains
unanswered: How is functional diversity and speciﬁcity of TGF-b
signaling achieved? Although TGF-b signaling likely uses ‘‘co-sig-
nals’’ from other morphogens such as Wnt or other cytokines
(see above), which by applying double morphogen gradients pre-
cisely determine cell differentiation and fate in a temporospatially
deﬁned manner, it cannot explain whether or not two TGF-b li-
gands will deliver the same qualitative and quantitative signal out-
put when using the same receptors. Such a situation would exist
in vivo during limb and joint development, where many different
TGF-b ligands act in a highly overlapping cellular space and their
overlapping receptor usage will inevitably lead to signaling inter-
ference (for review [131]). For instance, BMP-2 and GDF-5 (but also
other BMP factors) show expression patterns highly overlapping in
time and space in the developing limb and due to their promiscu-
ous receptor binding can form receptor assemblies with identical
composition. What is our expectation in such a case? If only com-
position deﬁnes signal outcome both ligands should encode the
same function and we would thus observe redundancy. However,
deletion studies of Gdf5 suggest that signaling of GDF-5 is different
from BMP-2 [34]. One could argue that the signaling of GDF-5 spe-
ciﬁcally through BMPR-IB might cause the different signaling and
reports indeed show that BMPR-IA and BMPR-IB can exert oppos-
ing effects [132]. In vitro cellular assays in two different cell lines
routinely used in BMP analysis, C2C12 and ATDC5, allowed study-
ing differences in signaling in more detail and a deﬁned back-
ground. As both cell lines C2C12 and ATDC5 seem not to express
the type I receptor or express BMPR-IB to a very low extent
[133,134], it is very likely that signaling of both ligands, BMP-2
and GDF-5, has to occur via the receptor BMPR-IA. Interestingly,
in C2C12 cells only BMP-2 but not GDF-5 can induce expression
Fig. 7. (A) NMR analysis of the free ligand-binding domain of BMPR-IA reveals a disordered and dynamic structure for the b4b5-loop, which constitutes a large part of the
binding epitope to BMP-2 (black box). (B) Upon binding to BMP-2 the ﬂexible element (marked in cyan) becomes structured and adopts a deﬁned structure comprising a short
1.5-turn helix. (C) The dynamic nature allows to adapt the loop conformation according to the needs of the binding partner as seen from the extended, but rigid conformation
of the loop element (marked in red) when bound to a neutralizing antibody. (D) A second loop element (marked by a red box in (A)) of the BMP type I receptors can exist in
two different conformations. In BMPR-IB (green) the b1b2-loop adopts an open conformation allowing the binding of BMP/GDF ligands with a large bulky residue (Arg57 in
GDF-5) in the ligand’s pre-helix loop. In BMPR-IA this loop is in a closed conformation resulting in a steric hindrance between a large side chain at position 57 and residues,
e.g. His43 in BMPR-IA (equivalent residues in BMPR-IB His23). Thus high-afﬁnity binding of BMPR-IA is only possible for ligands with small amino acids at the position
equivalent to Arg57 in GDF-5. BMPR-IB does not discriminate ligands with differing amino acid side chains at this position. (E) As in (D) but rotated around the x-axis by 90.
The conformational change is indicated by arrows. (F) TGF-b3 can exist in two conformations (differing by a rotation of 110 perpendicular to the intermolecular disulﬁde
bond) as seen from structure analysis of free TGF-b3 and TGF-b3 in complex with TbR-II (middle panel). For ternary complex formation a closed conformation is required for
binding of the type I receptor TbR-I (right panel). The switch between an open and closed ligand conformation might ensure a sequential binding mode and possibly increases
type I receptor speciﬁcity. (G) A ﬂexible dimer architecture is also seen for Activin-A. Structure analyses of free Activin-A and Activin-A bound to its type II receptor ActR-IIB
have revealed a wing ﬂap motion with a highly variable interdomain angle. (H) Superposition of the structures of BMP-2 (green and cyan) with different structures of Activin-
A in unbound conformation and in conformations bound to either ActR-IIB or follistatin indicating the high variability in dimer architecture. The different interdomain
orientations are indicated by numbers: 1 = BMP-2; 2 = Activin bound to Follistatin (PDB entries 2P6A and 2B0U); 3 = free Activin and Activin bound to ActR-IIB (PDB entries
2ARV and 1S4Y); 4 = Activin bound to a fragment of Follistatin (PDB entry 2ARP); 5 = Activin bound to ActR-IIB (PDB entry 1NYS).
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tase), whereas in ATDC5 cells both ligands do induce alkaline phos-
phatase (ALP) expression. Here, a tenfold higher concentration of
GDF-5 is required, which nicely correlates with the lower afﬁnity
for the BMPR-IA receptor [110]. To rule out that type I receptor
afﬁnity is responsible for the cell-speciﬁc differences in BMP-2
and GDF-5 mediated ALP expression, we used the GDF-5 variant
R57A, which exhibits the same binding afﬁnities for BMPR-IA and
thus can be considered a BMP-2 mimic (Klammert, U. et al. manu-
script in preparation). Despite its ability to form the same receptor
assembly with the same efﬁciency as BMP-2, GDF-5R57A did not
induce ALP expression in C2C12 cells. That GDF-5R57A indeedbinds to the same receptors as BMP-2 could be conﬁrmed in a com-
petition experiment showing that the variant inhibits BMP-2 activ-
ity in a dose-dependent manner (Klammert, U. et al. manuscript in
preparation). This indicates that the formation of a BMP receptor
complex of identical composition can be active for one particular
ligand, but silent for another suggesting that different TGF-b li-
gands might encode different intracellular signals despite using
identical receptor assemblies. Thus ligand–receptor promiscuity
is not automatically a direct evidence for functional redundancy.
So what are possible mechanisms that allow for a ligand-spe-
ciﬁc activation of otherwise identical receptor assemblies? One
possibility might be small ligand-speciﬁc structural differences in
T.D. Mueller, J. Nickel / FEBS Letters 586 (2012) 1846–1859 1857the complex architecture. Upon comparing the structures of differ-
ent BMP/GDF ligand–receptor complexes, we have found small dif-
ferences in the orientation of the type I receptors that, if translated
into the cytoplasm, might inﬂuence not only transactivation be-
tween receptors but also phosphorylation of substrates and hence
the downstream signaling cascade [101,111]. That signal transduc-
tion of single-span transmembrane receptors is not limited to
receptor oligomerization by just lateral movements in the mem-
brane, but might be modulated by vertical or rotational move-
ments as has already been demonstrated in several studies
[135,136]. The kinetics of the ligand–receptor interaction might
be an important factor for the speciﬁcity of downstream signals.
As the cytoplasmic receptor domains are kinases their substrate
afﬁnities and phosphorylation rate can be used to encode ligand-
speciﬁc signals, if the ligand–receptor complexes differ with re-
spect to their assembly lifetimes. We indeed have hints that the
kinetics and not only thermodynamics of the ligand–receptor
assembly might matter. Variants of GDF-5 exhibiting identical
afﬁnities for the BMP type I receptors as wildtype GDF-5, but dif-
fering in their binding kinetics do not activate gene expression in
cellular assays [111]. Thus triggering the same receptor assembly
but with a shorter lifetime might not activate downstream signal-
ing or restrain the set of signals. A third possibility might be the
involvement of co-receptors such as Cripto, endoglin, betaglycan
and others having their own ligand speciﬁcity proﬁle (see also
Fig. 3D). If having a cytoplasmic domain these could directly alter
signaling outcome. However also co-receptors without a cytoplas-
mic domain such as Cripto or the recently identiﬁed BMP-speciﬁc
co-receptors of the RGM family (for review [137]) can modulate
the signaling cascade in a ligand-speciﬁc manner by altering the
receptor binding speciﬁcity of individual TGF-b ligands. Thus a
large toolbox to enhance signaling diversity through a limited set
of receptors might exist and requires our future attention.
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